Dual beta-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment.
Codrugs comprise a beta-lactam-fluoroquinolone antibacterial hybrid. These new agents have been developed with the aim of enhancing the antibacterial spectrum of current therapies, overcoming intrinsic and acquired resistance, and diminishing severe side-effects. A few compounds, including Ro 23-9424, have entered Phase I clinical trials. Furthermore, a series of oral codrugs have been synthesised, although clear oral bioavailability has not yet been demonstrated. New drugs are urgently needed to treat Gram-positive resistant bacteria.
Hoechst Marion Roussel, Anti-infective Research Clinical Pharmacology, 102 Route de Noisy, 93230 Romainville Cedex, France.
A
A
Bryskier